

### 510(k) Summary

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact

Roche Diagnostics Corporation 9115 Hague Road Indianapolis, IN 46250 (317) 576 - 3544

Contact Person: Kay A. Taylor

Date Prepared: February 18, 2000

**Device Name** 

Proprietary name: Elecsys® Cortisol CalCheck

Common name: Calibration Verification Material

Classification name: Single (specified) analyte controls (assayed +

unassayed)

Predicate device

The Elecsys® Cortisol CalCheck is substantially equivalent to the currently

marketed Elecsys CalCheck TSH.

Device Description The Elecsys® Cortisol CalCheck is a lyophilized product manufactured using a human serum base, synthetic cortisol, and preservative. The analyte is appropriately spiked into the CalCheck matrix to the correct CalCheck

concentration levels.

# 510(k) Summary, Continued

Intended use	The Elecsys® Cortisol CalCheck is used to verify the calibration of the Elecsys® Cortisol assay.
Comparison to predicate device	The Elecsys® Cortisol CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. Most notably, it is substantially equivalent to the currently marketed Elecsys® CalCheck <sup>TM</sup> TSH.
	Both products are intended to be used for the verification of calibration for analytes on the Elecsys® Immunoassay Analyzers.
Performance Characteristics	The Elecsys® Cortisol CalCheck was evaluated for value assignment and stability.

#### **DEPARTMENT OF HEALTH & HUMAN SERVICES**



MAR 2 1 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Kay A. Taylor Regulatory Affairs, Laboratory Systems Roche Diagnostics Corporation 9115 Hague Road P.O. Box 50457 Indianapolis, Indiana 46250-0457

Re: K000576

Trade Name: Elecsys® Cortisol CalCheck

Regulatory Class: II Product Code: JIX

Dated: February 18, 2000 Received: February 22, 2000

#### Dear Ms. Taylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

#### Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Steven Butman

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## **Indications for Use Statement**

510(k) Number (if known): <u>N/A</u>	K00057	16
Device Name: <u>Elecsys® Cortisol</u> (	CalCheck	
Indications For Use:		
	efined Cortisol c ection limit of the point of the meas	
The Elecsys® Cortisol CalCheck is calibration of the Elecsys® Cortison		se in periodic verification of the
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use
		(Optional Format 1-2-96)
(Division Sign-Off) Division of Clinical Laborate 510(k) Number	1650 1657 (j	